(S)-3-Amino-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one → (4S,7S,10aS)-Methyl 4-((2R,5R)-2,5-dibenzyl-6-oxo-6-((S)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)hexanamido)-5-oxooctahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxylate

HRID 529582

反応式

HRID 529582 の反応式
[CH2:1]([C@@H:8]([CH2:12][CH2:13][C@H:14]([CH2:34][C:35]1[CH:40]=[CH:39][CH:38]=[CH:37][CH:36]=1)[C:15]([NH:17][C@H:18]1[CH2:24][CH2:23][S:22][C@H:21]2[CH2:25][CH2:26][CH2:27][C@@H:28]([C:29]([O:31][CH3:32])=[O:30])[N:20]2[C:19]1=[O:33])=[O:16])[C:9](O)=[O:10])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.[NH2:41][C@@H:42]1[C:48](=[O:49])[NH:47][C:46]2[CH:50]=[CH:51][CH:52]=[CH:53][C:45]=2[CH2:44][CH2:43]1>>[CH2:34]([C@@H:14]([CH2:13][CH2:12][C@H:8]([CH2:1][C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1)[C:9](=[O:10])[NH:41][C@@H:42]1[C:48](=[O:49])[NH:47][C:46]2[CH:50]=[CH:51][CH:52]=[CH:53][C:45]=2[CH2:44][CH2:43]1)[C:15]([NH:17][C@H:18]1[CH2:24][CH2:23][S:22][C@H:21]2[CH2:25][CH2:26][CH2:27][C@@H:28]([C:29]([O:31][CH3:32])=[O:30])[N:20]2[C:19]1=[O:33])=[O:16])[C:35]1[CH:36]=[CH:37][CH:38]=[CH:39][CH:40]=1

参加物

3

実験手順

(4S,7S,10aS)-Methyl 4-((2R,5R)-2,5-dibenzyl-6-oxo-6-((S)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)hexanamido)-5-oxooctahydro-2H-pyrido[2,1-b][1,3]thiazepine-7-carboxylate was synthesized as described in General Procedure H using Intermediate 23 (5.0 mg, 0.0088 mmol) and (S)-3-amino-4,5-dihydro-1H-benzo[b]azepin-2(3H)-one (1.6 mg, 0.0088 mmol) to give a white solid (5.1 mg, 80% yield). Anal. Calcd. for C41H48N4O6S m/z 724.9. found: 725.3 (M+H)+; 1H NMR (400 MHz, CDCl3) δ ppm 7.24-6.90 (m, 14H), 6.28-6.20 (m, 1H), 5.29-5.20 (m, 1H), 5.04-4.97 (m, 2H), 4.93-4.84 (m, 2H), 4.30-4.20 (m, 1H), 3.60-3.53 (m, 3H), 3.20-3.04 (m, 1H), 2.82-2.50 (m, 8H), 2.37-2.19 (m, 4H), 1.96-1.88 (m, 2H), 1.85-1.68 (m, 2H), 1.67-1.31 (m, 6H), 1.27-1.14 (m, 1H).

出典と根拠

ORDレコード
ord-37c0ae2b41984407aebf9d5df7fd1712
出典データセット
uspto-grants-2016_05
特許番号
US09346852B2

関連ノート

読み込み中…